Biweekly paclitaxel, cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy for unresectable squamous cell carcinoma of the head and neck

Cancer

Volumn 101, Issue 8, 2004, Pages 1818-1823

  Wang, Hung Ming ^a   Liao, Chun Ta ^a   Chang, Tung Chieh Joseph ^a   Chen, Jen Shi ^a   Liaw, Cuang Chi ^a   Chen, I How ^a   Tsang, Ngan Ming ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Head and neck neoplasms; Paclitaxel; Squamous cell carcinoma; Tegafur

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; DEXAMETHASONE; FOLINIC ACID; METOCLOPRAMIDE; ONDANSETRON; PACLITAXEL; TEGAFUR; TROPISETRON;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; INOPERABLE CANCER; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 4744370569     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20561     Document Type: Article

References (30)

1. Department of Health, Executive Yuan, Taiwan, R.O.C. [Cancer registry: annual report in Taiwan area, 1997]. Taipei: Department of Health, Executive Yuan, 2000.
2. Stell PM. Adjuvant chemotherapy in head and neck cancer. Semin Radiat Oncol. 1992;2:195-205.
3. Munro AJ. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995;71:83-91.
4. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol. 1996;14:838-847.
5. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:945-955.
6. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994;86:265-272.
7. Posner MR, Colevas AD, Tishler RB. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol. 2000;27(4 Suppl 8):13-24.
8. Wang HM, Wang CH, Chen JS, Chen IH, Liao CT, Chang TC. Cisplatin, tegafur and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002;94:2989-2995.
9. Wang HM, Wang CH, Chen JS, et al. Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer. J Formos Med Assoc. 1995;94:87-94.
10. Wang HM, Wang CH, Chen JS, Su CL, Liao CT, Chen IH. Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent. Am J Clin Oncol. 1999;22:485-488.
11. Forastiere AA, Shank D, Neuberg D, Taylor SG IV, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer. 1998;82:2270-2281.
12. Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol. 1995;22(3 Suppl 6):41-46.
13. Shin DM, Lippman SM. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Semin Oncol. 1999;26(1 Suppl 2):100-105.
14. Gelmon KA, Tolcher AW, O'Reilly SE, et al. A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer. Ann Oncol. 1998;9:1247-1249.
15. Gelmon KA, O'Reilly SE, Tolcher AW, et al. A phase I/II study of bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol. 1996;14:1185-1191.
16. Sparano JA, Neuberg D, Glick JH, et al. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1997;15:1880-1884.
17. Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1998.
18. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an effective drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672-1678.
19. Benasso M, Numico G, Rosso R, Merlano M, Ricci I, Gentile A. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naïve patients. A dose-finding study. Semin Oncol. 1997;24(6 Suppl 19):S19-46-S19-50.
20. Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer. 1999;86:2364-2369.
21. Hainsworth JD, Burris HA III, Meluch AA, Baker MN, Morrissey LH, Greco FA. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial. Cancer. 2001;92:642-649.
22. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 1993;85:95-111.
23. Licitra L, Capri G, Fulfaro F, et al. Bi-weekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. Ann Oncol. 1997;8:1157-1158.
24. Gelmon KA, Tolcher AW, O'Reilly SE, et al. A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer. Ann Oncol. 1998;9:1247-1249.
25. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer. Eastern Cooperative Oncology Group study E1393. J Clin Oncol. 2001;19:1088-1095.
26. Takimoto CH, Rowinsky EK. Dose-intense paclitaxel: deja vu all over again? J Clin Oncol. 2003;21:2810-2814.
27. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003;21:320-326.
28. Johnson KR, Wang L, Miller MC III, Willingham MC, Fan W. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res. 1997;3:1739-1745.
29. Grem JL, Nguyen D, Monahan BP, Kao V, Geoffroy FJ. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol. 1999;58:477-486.
30. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusion paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001;19:1961-1969.